Page 109 - Read Online

Jia et al. Cancer Drug Resist 2019;2:210-24 I http://dx.doi.org/10.20517/cdr.2018.010 Page 221

27. Pihan GA, Wallace J, Zhou Y, Doxsey SJ. Centrosome abnormalities and chromosome instability occur together in pre-invasive
carcinomas. Cancer Res 2003;63:1398-1404.
28. Chan JY. A clinical overview of centrosome amplification in human cancers. Int J Biol Sci 2011;7:1122-44.
29. Kwon M, Godinho SA, Chandhok NS, Ganem NJ, Azioune A, et al. Mechanisms to suppress multipolar divisions in cancer cells with
extra centrosomes. Genes Dev 2008;22:2189-203.
30. Neben K, Giesecke C, Schweizer S, Ho AD, Krämer A. Centrosome aberrations in acute myeloid leukemia are correlated with cytogenetic
risk profile. Blood 2003;101:289-91.
31. Mahathre MM, Rida PC, Aneja R. The more the messier: centrosome amplification as a novel biomarker for personalized treatment of
colorectal cancers. J Biomed Res 2015;30:441-51.
32. Kais Z, Parvin JD. Regulation of centrosomes by the BRCA1-dependent ubiquitin ligase. Cancer Biol Ther 2008;7:1540-3.
33. Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude GF. Abnormal centrosome amplification in the absence of p53. Science
1996;271:1744-7.
34. Li X, Song N, Liu L, Liu X, Ding X, et al. USP9X regulates centrosome duplication and promotes breast carcinogenesis. Nat Commun
2017;8:14866.
35. Xie S, Qin J, Liu S, Zhang Y, Wang J, et al. Cep70 overexpression stimulates pancreatic cancer by inducing centrosome abnormality and
microtubule disorganization. Sci Rep 2016;6:21263.
36. Denu RA, Zasadil LM, Kanugh C, Laffin J, Weaver BA, et al. Centrosome amplification induces high grade features and is prognostic of
worse outcomes in breast cancer. BMC Cancer 2016;16:47.
37. Miyachika Y, Yamamoto Y, Matsumoto H, Nishijima J, Kawai Y, et al. Centrosome amplification in bladder washing cytology specimens
is a useful prognostic biomarker for non-muscle invasive bladder cancer. Cancer Genet 2013;206:12-8.
38. Zeng YR, Han ZD, Wang C, Cai C, Huang YQ, et al. Overexpression of NIMA-related kinase 2 is associated with progression and poor
prognosis of prostate cancer. BMC Urol 2015;15:90.
39. Ogden A, Rida PC, Aneja R. Prognostic value of CA20, a score based on centrosome amplification-associated genes, in breast tumors. Sci
Rep 2017;7:262.
40. Huang J, Sun SG, Hou S. Aberrant NEK2 expression might be an independent predictor for poor recurrence-free survival and overall
survival of skin cutaneous melanoma. Eur Rev Med Pharmacol Sci 2018;22:3694-3702.
41. Yun M, Rong J, Lin ZR, He YL, Zhang JX, et al. High expression of transforming acidic coiled coil-containing protein 3 strongly
correlates with aggressive characteristics and poor prognosis of gastric cancer. Oncol Rep 2015;34:1397-1405.
42. Karkera JD, Cardona GM, Bell K, Gaffney D, Portale JC, et al. Oncogenic characterization and pharmacologic sensitivity of activating
fibroblast growth factor receptor (FGFR) genetic alterations to the selective FGFR inhibitor erdafitinib. Mol Cancer Ther 2017;16:1717-26.
43. Lauffart B, Vaughan MM, Eddy R, Chervinsky D, DiCioccio RA, et al. Aberrations of TACC1 and TACC3 are associated with ovarian
cancer. BMC Women’s Health 2005;5:8.
44. Fan G, Sun L, Shan P, Zhang X, Huan J, et al. Loss of KLF14 triggers centrosome amplification and tumorigenesis. Nat Commun
2015;6:8450.
45. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, et al. A landscape of driver mutations in melanoma. Cell 2012;150:251-63.
46. Tamotsu K, Okumura H, Uchikado Y, Kita Y, Sasaki K, et al. Correlation of Aurora-A expression with the effect of chemoradiation
therapy on esophageal squamous cell carcinoma. BMC Cancer 2015;15:323.
47. Rakha EA, Pinder SE, Paish CE, Ellis IO. Expression of the transcription factor CTCF in invasive breast cancer: a candidate gene located
at 16q22.1. Br J Cancer 2004;91:1591-6.
48. Lee J, Gollahon L. Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triplenegative breast cancer cells.
Int J Oncol 2013;42:839-47.
49. Zhou W, Yang Y, Xia J, Wang H, Salama ME, et al. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is
associated with poor prognosis in myeloma and other cancers. Cancer Cell 2013;23:48-62.
50. Liu X, Gao Y, Lu Y, Zhang J, Li L, et al. Upregulation of NEK2 is associated with drug resistance in ovarian cancer. Oncol Rep
2014;31:745-54.
51. Wu SM, Lin SL, Lee KY, Chuang HC, Feng PH, et al. Hepatoma cell functions modulated by NEK2 are associated with liver cancer
progression. Int J Cancer 2017;140:1581-96.
52. Zhao W, Song Y, Xu B, Zhan Q. Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to paclitaxel. Cancer
Biol Ther 2012,13:156-63.
53. Kleylein-Sohn J, Pöllinger B, Ohmer M; Hofmann F, Nigg EA, Hemmings, et al. Acentrosomal spindle organization renders cancer cells
dependent on the kinesin HSET. J Cell Sci 2012;125:5391-402.
54. Kwon M, Bagonis M, Danuser G, Pellman D. Direct microtubule-binding by myosin-10 orients centrosomes toward retraction fibers and
subcortical actin clouds. Dev Cell 2015;34:323-37.
55. De S, Cipriano R, Jackson MW, Stark GR. Overexpression of kinesins mediates docetaxel resistance in breast cancer cells. Cancer Res
2009;69:8035-42.
56. Li JJ, Weroha SJ, Lingle WL, Papa D, Salisbury JL, et al. Estrogen mediates Aurora-A overexpression, centrosome amplification,
chromosomal instability, and breast cancer in female ACI rats. Proc Natl Acad Sci USA 2004;101:18123-8.
57. Marina M, Saavedra HI. Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance. Front Biosci (Landmark
Ed) 2014;19:352-65.
58. Jusino S, Fernández-Padín FM, Saavedra HI. Centrosome aberrations and chromosome instability contribute to tumorigenesis and intra-tumor